2-Fluorodeschloroketamine (also known as 2'-Fl-2-Oxo-PCM, Fluoroketamine and 2-FDCK) is a
dissociativeanesthetic[1] related to
ketamine. Its sale and use as a
designer drug has been reported in various countries.[2][3][4] It is an analogue of ketamine where the
chlorine group has been replaced by
fluorine. Due to its recent emergence, the pharmacological specifics of the compound are mostly unclear, but effects are reported to be similar to its parent compound, ketamine.
History
The synthesis of 2-FDCK was first described in a 2013 paper as part of a larger effort to synthesize and evaluate new anesthetic drugs based on ketamine and its analogues.[1] Ketamine itself was first introduced in 1964 and was approved for clinical use in 1970. Since then it has become one of the most important and applicable general anesthetics as well as a popular recreational drug.
The use of 2-FDCK as a research chemical has been reported in various countries.[2][5][6] Many of these new psychoactive substances (
NPS) appear on the drug market in order to circumvent existing drug policies. 2-FDCK was first formally notified by the
EMCDDA in 2016, alongside 65 other new substances.[6] Due to its recent appearance, little research has been done on the compound so far.
In January 2023, Israeli Biotech company "Clearmind Medicine Inc." announced the successful completion of a preclinical study examining 2-FDCK in a rat model of depression, with the compound outperforming ketamine in longevity of antidepressant effect.[7]
Chemistry
Structure
The full chemical name of 2-FDCK is 2-(2-fluorophenyl)-2-(methylamino)cyclohexan-1-one.
2-FDCK belongs to a class of compounds called
arylcyclohexylamines which contains various other drugs such as
PCP and
ketamine. Their general structure consists of a
cyclohexylamine unit with an
aryl group attached to the same carbon as the
amine. 2-FDCK has an o-fluorophenyl group as an aryl substituent and the amine group is methylated. The cyclohexyl ring features a
ketone group next to the amine position.
The chemical structure of 2-FDCK differs from ketamine only in that there is a fluorine atom attached to the phenyl group. Ketamine has a chlorine atom in that position.[8]
Synthesis
2-FDCK can be synthesized in a five-step reaction process.[1] First 2-fluorobenzonitrile reacts with the
Grignard reagent cyclopentyl magnesium bromide followed by a
bromination reaction to obtain α-bromocyclopentyl-(2-fluorophenyl)-ketone. The reaction of the obtained ketone with methylamine at -40 °C then results in the formation of α-hydroxycyclopentyl-(2-fluorophenyl)-N-methylamine. Finally, the five-membered ring cyclopentanol form is expanded to a cyclohexylketone form by a thermal rearrangement reaction.
HCl is used to create a water-soluble HCl salt of 2-FDCK.
Detection
2-FDCK and its metabolites can be detected in
urine with the use of liquid chromatography mass spectrometry (
LC/MS).[4][9]
Pharmacology
Metabolism
The metabolism of 2-FDCK is analogous to that of ketamine: the enzymes
CYP2B6 and
CYP3A4, the latter to a lesser extent, metabolise 2-FDCK to Nor-2FDCK via
N-demethylation. This is further metabolised either to dehydronor-2FDCK by CYP2B6 or to hydroxynor-2FDCK by
CYP2A6 and CYP2B6.[3]
In general, the 2-FDCK equivalent shows stronger
docking to CYP2B6 in simulations, as well as slower metabolism rate, than the more well-known ketamine. The
lipophilicity is observed to be lower for 2-FDCK than for ketamine.[3]In vitro to in vivo extrapolation predicts that in the body, 2-FDCK shows a lower intrinsic hepatic
clearance than ketamine. Both of these characteristics would suggest that the effects of 2-FDCK last longer than those of ketamine.[2]
Pharmacodynamics
2-FDCK is structurally similar to ketamine, so a similar mechanism of action is expected,[10] but there has been no study done to confirm this. Due to the halogen in the 2 position not being a chlorine but a fluorine, the molecule is less polar.[3] This could influence
binding to proteins, such as the
NMDA receptor that ketamine primarily binds to and acts as an
antagonist towards.
Comparison to other halogen-substituted ketamine variants
For general (halogen) substitutions of ketamine, docking strength for CYP2B6 follows the pattern H < Br < Cl < F. The parameter of internal clearance follows the pattern Br > Cl > F > H. Lastly, Km (
Michaelis constant) follows the pattern of Br < Cl < F < H, and as such the in-vitro metabolism rate follows the inverse pattern, namely Br > Cl > F > H.[4]
Adverse effects
Possible effects and dangers
In 2019, 2-FDCK was found in poisoned individuals in Hong Kong in combination with other ketamine-type drugs.[4]
Legal status
Due to the fast emergence of
NPS, new substances such as 2-FDCK are often not yet specifically mentioned in
controlled substance legislation. As a result,
NPS are sometimes marketed as '
legal highs'. 2-FDCK is currently illegal in Italy[11] Japan,[12] Latvia,[13] Singapore,[14] Sweden,[15] Switzerland,[16] as well as being covered by blanket bans in Canada,[17] Belgium,[18] and the UK.[19]
^
abcDavidsen AB, Mardal M, Holm NB, Andreasen AK, Johansen SS, Noble C, et al. (February 2020). "Ketamine analogues: Comparative toxicokinetic in vitro-in vivo extrapolation and quantification of 2-fluorodeschloroketamine in forensic blood and hair samples". Journal of Pharmaceutical and Biomedical Analysis. 180: 113049.
doi:
10.1016/j.jpba.2019.113049.
PMID31881397.
S2CID209499229.
^
abcdTang MH, Li TC, Lai CK, Chong YK, Ching CK, Mak TW (July 2020). "Emergence of new psychoactive substance 2-fluorodeschloroketamine: Toxicology and urinary analysis in a cluster of patients exposed to ketamine and multiple analogues". Forensic Science International. 312: 110327.
doi:
10.1016/j.forsciint.2020.110327.
PMID32460225.
S2CID218954528.
^
abEuropean Monitoring Centre for Drugs and Drug Addiction (2017), EMCDDA–Europol 2016 Annual Report on the implementation of Council Decision 2005/387/JHA, Implementation reports, Publications Office of the European Union, Luxembourg.
^Morris H, Wallach J (2014). "From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs". Drug Testing and Analysis. 6 (7–8): 614–632.
doi:
10.1002/dta.1620.
PMID24678061.
^"Article 1". Aggiornamento delle tabelle contenenti l'indicazione delle sostanze stupefacenti e psicotrope, di cui al decreto del Presidente della Repubblica 9 ottobre 1990, n. 309 e successive modificazioni ed integrazioni. Inserimento nella tabella I e nella tabella IV di nuove sostanze psicoattive (in Italian). March 13, 2020.
^"指定薬物一覧" (PDF) (in Japanese). Ministry of Health, Labour and Welfare